

ORIGINAL RESEARCH

A Correlative Study of Serum Fibrinogen Levels, BMI and Lipid Profile in Type 2 Diabetes Mellitus with Hypertension

¹Dr. Pinniboyana Vijaya Kumar, ²Dr. Pinniboyana Sri Harshitha, ³Dr. Gridhati Srinivas

¹MBBS, MD, Associate Professor, Department of Emergency Medicine, Narayana Medical College, Nellore, Andhra Pradesh, India

²MBBS, MD, Senior Resident, ³MBBS, MD, Senior Resident, Department of General Medicine, Narayana Medical College, Nellore, Andhra Pradesh, India

Corresponding Author

Dr. Pinniboyana Vijaya Kumar

MBBS, MD, Associate Professor, Department of Emergency Medicine, Narayana Medical College, Nellore, Andhra Pradesh, India

Received: 15 February, 2023

Accepted: 21 March, 2023

ABSTRACT

Aim: To estimate serum fibrinogen levels in patients with type 2 diabetes mellitus and hypertension and also to correlate serum fibrinogen with BMI and lipid profile parameters. **Material and Methods:** The present study was conducted on 135 patients at Narayana Medical College, Nellore during March 2022 to December 2022. Patients are divided into a study group and a control group. **Results:** Higher serum fibrinogen levels were found in diabetic hypertensive patients (444.30 ± 63.58). There was a significant positive correlation between serum fibrinogen and BMI ($p < 0.05$). There was a significant positive correlation between BMI and total cholesterol levels ($p < 0.05$). There was a significant positive correlation of serum fibrinogen with total cholesterol, TCH/HDL, and triglycerides. **Conclusion:** It can be concluded from the results that Type 2 Diabetics with hypertension have elevated fibrinogen levels related to BMI and total cholesterol, TCH/HDL and triglyceride levels in a statistically significant manner.

Keywords: Body Mass Index, Fibrinogen, Total Cholesterol, Triglycerides.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

INTRODUCTION

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage/dysfunction and various organ's failure, especially the eyes, kidneys, nerves, heart, and blood vessels. Diabetes is an "Iceberg" disease. According to recent estimates, the prevalence of diabetes mellitus in adults is around 4% worldwide. It is projected that the disease prevalence will be 5.4% by the year 2025, with the global diabetic population reaching 300 million. Of this, close to 77% of the global burden of disease is projected to occur in developing countries¹.

Type 2 Diabetes Mellitus forms 95% of all diabetics. An estimated 30 million persons in the South East Asian region are affected at present. It is estimated that by the year 2025, there will be nearly 80 million

diabetics in this region, the highest among all WHO regions. The greatest increase will be in India, i.e., from 19.4 million (1995) to 57.2 million by 2025. The prevalence of diabetics in Indian adults was 2.4% in rural and 4-11.6% in urban dwellers². The aim of the study was to estimate and correlate the serum fibrinogen levels, BMI and lipid profile in type 2 diabetes mellitus with hypertension.

MATERIAL AND METHODS

The patients diagnosed with type 2 Diabetes mellitus with hypertension coming to Narayana Medical College, Nellore during March 2022 to December 2022. Controls were subjects who do not have type 2 diabetes mellitus and hypertension. 135 patients were selected randomly and divided into case ($n=80$) and control ($n=55$).

INCLUSION CRITERIA

1. All patients with a diagnosis of type 2 diabetes mellitus with hypertension.
2. Patients who are willing to participate in the study and have given written consent.

EXCLUSION CRITERIA

1. Type 1 Diabetes mellitus patients.
2. Patients with abnormal lipid profile secondary to hypothyroidism, alcoholic liver disease, renal failure and nephrotic syndrome.
3. Patients on drugs like Glucocorticoids, estrogens and progesterons.
4. Patients with a history of familial dyslipidemia.
5. Pregnant women.
6. Patients with a known history of coronary artery disease.

Method Followed

1. Anthropometric parameters of obesity as per WHO recommendations.
2. Fasting serum lipid profile cholesterol and triglyceride measurements were performed by using standard enzymatic techniques: LDL-cholesterol was calculated by using the formula of Friedewald et al.³
3. Venous plasma glucose was measured by the glucose oxidase method.
4. Plasma fibrinogen was measured by the Clauss method.

MEASUREMENT PROTOCOLS

1. **Height:** It was measured against a vertical board with an attached metric rule, and a horizontal headboard was brought in contact with the uppermost point on the head. It was recorded barefoot, with a person standing on a flat surface and weight distributed evenly on both feet and heels together and the head positioned so that the line of vision is perpendicular to the body. The arms should be hanging freely by the sides, and the head, back, buttocks and heels should be in contact with the vertical board. The individual was asked to inhale deeply and maintained a fully erect position. The topmost point on the head with sufficient pressure to compress the hair was taken as height to the nearest of 0.1 cm.⁴
2. **Weight:** Weight was recorded without footwear with light clothes worn on the body, standing straight on the center of the weighing machine with bodyweight evenly distributed between both feet by the ISI certified weighing machine to the nearest of 100 gms.⁴
3. **Body Mass Index:** Calculated as $w\text{t (kg)}/h\text{t}^2(\text{m}^2)$
4. **Waist circumference:** It was measured in centimeters with a flexible measuring tape, midway between the inferior margin of the last rib and crest of the ilium in the horizontal plane,

at the end of expiration, to the nearest of 0.1 cm. The tape should not compress the underlying soft tissues.⁴

5. **Hip circumference:** It was also measured in centimeters with a flexible measuring tape at the level of maximum extension of buttocks (greater trochanter) bilaterally in the horizontal plane with the subject standing with arms at the sides and feet together with light clothes over the body.⁴
6. **Waist-hip ratio – WC/HC.**
7. **Blood pressure:** After the initial screening, confirmation of hypertension diagnosis is based on the average of 2-3 readings taken at each of two or more visits at least one week apart. Preferably a standard mercury sphygmomanometer should be used.

STATISTICAL METHOD

Statistical analysis of our study was performed using the statistical software package of social science version 21(SPSS). The results of continuous variables are given as mean \pm SD and proportion as a percentage. Comparison of various parameters among male and female subjects with or without diabetes and hypertension was performed by t-test. Correlation between two variables was done by Pearson's correlation coefficient and chi-square test. For all the tests, a 'p' value of <0.05 was considered statistical significance.

RESULTS

56.3% of cases were males against 43.8% of females. 67.3% of controls were males against 32.7% of females. The youngest case observed in the present study was 40 years old, and the oldest case observed in the present study was 84 years old. The study group's mean age was 59.06 ± 10.34 years, and the control group was 55.6 ± 9.98 years. Male diabetic hypertensives had higher waist circumference, hip circumference, waist-hip ratio, and BMI than the control group's males. The difference was statistically significant. Similar results were also seen between female diabetic hypertensives and female controls, as shown in Table 1. Though the table shows that controls had higher height and weight values than the cases, the BMI calculation shows that the cases were overweight or obese compared to the controls. The lower weight in the cases may be due to diabetes. Elevated levels of serum triglycerides, VLDL-cholesterol, LDL cholesterol, total cholesterol, TCH-HDL ratio and low levels of HDL-cholesterol were observed among male and female diabetic hypertensives compared to male and female controls. The difference was statistically significant (table 2). All controls had normal serum fibrinogen. The mean serum fibrinogen levels in cases and controls were 444.30 ± 63.58 mg/dl and 223.91 ± 25.38 mg/dl, respectively as shown in the table 3. Elevated serum fibrinogen levels were observed among male and female diabetic hypertensives compared to male and

female controls. The difference was statistically significant.

Body Mass Index (BMI) is positively correlated to total cholesterol, TC-HDL-C ratio, triglycerides and LDL-C and negatively correlated to HDL-C levels. Still, a significant correlation was found between BMI and total cholesterol, as shown in the table 4.

Serum fibrinogen was positively correlated to total cholesterol, TC/HDL-C, triglycerides and LDL-C, negatively correlated to HDL-C levels. A significant correlation was found between serum fibrinogen, total cholesterol, TCH/HDL-C and Triglycerides, as shown in Table 5. Serum fibrinogen is positively correlated to BMI, which is statistically significant.

Table 1: Showing comparison of mean values of various anthropometric parameters of obesity between two groups

Parameters	Gender	Cases	Controls	P-value	Inference
Height (in cm)	Male	162.64 ± 6.523	168.22 ± 3.326	0.001	S
	Female	148.89 ± 3.270	162.17 ± 3.823	0.003	S
Weight (in Kgs)	Male	67.89 ± 8.454	68.19 ± 5.962	0.182	NS
	Female	59.91 ± 7.694	60.39 ± 7.437	0.218	NS
BMI (Body mass index) (kg/m ²)	Male	25.85 ± 4.337	24.13 ± 2.471	0.035	S
	Female	27.01 ± 3.195	23.07 ± 3.539	0.001	S
WC (Waist Circumference (in cm))	Male	101.20 ± 5.953	93.76 ± 7.584	0.000	S
	Female	99.97 ± 5.415	79.78 ± 2.315	0.000	S
HC (Hip circumference) (in cm)	Male	98.27 ± 2.263	97.08 ± 2.994	0.043	S
	Female	103.97 ± 5.685	93.89 ± 3.123	0.000	S
W/H ratio (Waist/Hip ratio)	Male	1.03 ± 0.081	0.97 ± 0.111	0.006	S
	Female	0.96 ± 0.039	0.85 ± 0.039	0.000	S

Table 2: Showing comparison of mean values of fasting serum lipid profile between two groups

Parameter	Gender	Cases (n=80)	Control (n=55)	P-value	Inference
Total Cholesterol	Male	190.64 ± 36.873	168.49 ± 17.958	0.002	S
	Female	197.34 ± 28.865	164.61 ± 26.255	0.000	S
HDL Cholesterol	Male	37.87 ± 4.143	45.38 ± 4.355	0.001	S
	Female	38.14 ± 3.607	49.11 ± 7.307	0.000	S
VLDL Cholesterol	Male	52.27 ± 12.992	30.70 ± 3.950	0.000	S
	Female	46.74 ± 12.120	21.56 ± 5.690	0.001	S
LDL Cholesterol	Male	100.51 ± 9.718	92.41 ± 17.517	0.010	S
	Female	112.46 ± 24.273	93.94 ± 26.928	0.014	S
Triglycerides	Male	261.53 ± 65.035	153.43 ± 19.867	0.000	S
	Female	233.66 ± 60.541	107.61 ± 28.049	0.000	S
TCH/HDL ratio	Male	5.09 ± 1.104	3.73 ± 0.433	0.000	S
	Female	5.22 ± 0.944	3.39 ± 0.561	0.000	S

Table 3: Showing fibrinogen distribution

Serum Fibrinogen (mg/dl)	Cases			Controls		
	Male	Female	Total	Male	Female	Total
150 - 300	2 (2.5%)	1 (1.3%)	3 (3.8%)	37 (67.3%)	17 (30.9%)	54 (98.2%)
301 - 450	12 (15.0%)	9 (11.3%)	21 (26.3%)	0 (.0%)	1 (1.8%)	1 (1.8%)
> 450	31 (38.8%)	25 (31.3%)	56 (70.0%)	0 (.0%)	0 (.0%)	0 (.0%)
Total	45 (56.3%)	35 (43.8%)	80 (100.0%)	37 (67.3%)	18 (32.7%)	55 (100.0%)
Mean \pm SD	433.87 \pm 61.558	457.71 \pm 64.512	444.30 \pm 63.588	221.32 \pm 19.284	229.22 \pm 34.854	223.91 \pm 25.384

Table 4: Showing correlation coefficient between BMI and lipid profile

	BMI	p-value	Inference
Total Cholesterol	0.196	0.023	P<0.05
HDL Cholesterol	-0.259	0.002	P<0.01
TCH/ HDL ratio	0.032	0.975	P>0.05
Triglycerides	0.042	0.626	P>0.05
LDL Cholesterol	0.003	0.712	P>0.05

Table 5: Showing correlation coefficient between Fibrinogen and lipid profile

	Fibrinogen	p-value	Inference
Total Cholesterol	0.319	0.000	P<0.001
HDL Cholesterol	-0.619	0.000	P<0.001
TCH/ HDL ratio	0.578	0.000	P<0.001
Triglycerides	0.595	0.000	P<0.001
LDL Cholesterol	0.165	0.058	P>0.05

DISCUSSION

A strong association of fibrinogen level with age has been found in our study. The level of fibrinogen rises with age. In the Lowe GDO study,⁵ the mean fibrinogen concentration increased steadily from 2.0 g/L in young adults to about 3.0 g/L in the elderly. The crude rate of increase in fibrinogen concentration was 1% per year over the whole group. Plasma fibrinogen levels in men rise with age than in women. Bruno G et al study⁶, Temelkova et al⁷, Lam TH et al⁸, Om P. Ganda⁹, Bruno y al¹⁰ and Christophe Tribonilloy et al¹¹ were other studies in which age had been positively associated with fibrinogen level. However, there was no association between age and fibrinogen level in Raynand's E et al¹² studies.

The mean age of diabetic hypertensives in both men and women is far higher than controls. Ibe et al¹³, Han et al¹⁴ and Sosenko et al¹⁵ have noted related observations. It suggests that as the mean age in the population advances, the number of people with diabetes and hypertension also increases.

67.3% of controls were males against 32.7% of females, and 56.3% of cases were males against 43.8% of females in our present study. The mean fibrinogen levels of females in this sample were higher than that of males. The fibrinogen concentration in Gary TC Koet al¹⁶, increased by 18.5 percent in his study of 101 diabetic participants from 3.53 (1.06) g/L baseline to 3.97 (1.07) g/L. The increase was 15.5% in men and 9.5% in women, representing a change of 6.7% in men and 8.1% in women per year, respectively.

The other studies which found higher fibrinogen values in females compared to males were Balleisen L et al¹⁷ study, Mariskaret al¹⁸ study, William B Kannel et al¹⁹ study and Folsom AR et al²⁰ study.

The mean BMI for males with diabetic hypertension is 25.85 kg/m², and for females with diabetic hypertension being 27.01 kg/m², with total mean in

cases was 26.36 kg/m², which was more than the mean of controls (23.78 kg/m²). Ibe et al¹⁴ and Han et al¹⁵ noted similar findings in their studies. In a study by Stefania Lamon-Fava et al²¹, it is observed that increased BMI is associated with a three-fold increased risk of CAD than in subjects with low BMI and also reported the same in studies conducted by Manson JE et al²², Curb JD et al²³, and Van Itallie TB²⁴.

The mean serum fibrinogen levels in diabetic hypertensives were significantly raised compared to controls. Similar results were observed by Barbara Glowinska et al²⁵ and Anjula Jain et al²⁶. Mean Fibrinogen was elevated in patients with diabetes mellitus compared with non-diabetics in a Bruno et al. study with 1574 people with diabetes in northern Italy. Similarly, Jensen et al. reported a steady rise in the amount of fibrinogen in complicated diabetics.²⁷ The mean value of fibrinogen was considerably higher in patients with coronary artery disease than in controls. It appeared to be higher in people with diabetes than in non-diabetics in a study performed by Eriksson et al in the Stockholm area.²⁸

There was a positive correlation between Body Mass Index and Total Cholesterol, which was statistically significant. Similar results were observed by Subhankar Chowdury et al²⁹ and Hideki et al³⁰. In a study conducted by Om P. Ganda et al³¹, BMI was significantly and linearly associated with hypertension, fasting glucose levels, total serum cholesterol, VLDL and LDL cholesterol and inversely related HDL cholesterol, which are the risk factors of CAD.

A positive correlation was found between serum fibrinogen levels and total cholesterol, which was statistically significant. Similar results were observed by Anjula Jain et al²⁶, Barbara Glowinska et al²⁵ studies. In the present study, cholesterol level, serum triglyceride level, and LDL level were positively

correlated with fibrinogen, and HDL cholesterol was negatively correlated with fibrinogen. The Gary TC Koet al¹⁶ analysis shows only changes in the plasma concentration of triglycerides to be in line with changes in fibrinogen levels.

Om P. Ganda et al³¹ in their study, found a positive correlation of fibrinogen level with total cholesterol but not with triglycerides and HDL cholesterol. Resch KL⁷³ and Ernst E also found a positive correlation among plasma fibrinogen level, total cholesterol and LDL cholesterol. Our present study observed a negative correlation between serum fibrinogen level and HDL-cholesterol. Similar results were observed by Resch K Let al³².

A significant positive correlation was found between serum fibrinogen and BMI. Similar results were observed by Anjula Jain et al²⁶ and Barbara Glowinska et al²⁵. In the study, there was a positive correlation between serum mean fibrinogen value and BMI. In the study of Ditschumit HH et al³³ found that obesity was independently related to mean fibrinogen level and fibrinogen level decreased after reduction of weight. Tribouilloy et al¹¹, in their study, found that fibrinogen levels were higher in those who were obese with a BMI of more than 30 Kg/m². In the study of Balleisen Let al¹⁷, the correlation between fibrinogen and body weight was more striking in females than in males, irrespective of age and pill usage.

LIMITATIONS

1. The total number of patients studied was a small number. Only 80 cases and 55 controls have been studied.
2. The controls have been selected by simple random sampling. So the higher weight and height observed in the present study may not be significant.
3. Common dyslipidemia encountered in the Asian population is hypertriglyceridemia. So, hypertriglyceridemia encountered in the present study may not be significant.
4. The lower body weight values noted in the cases compared to controls may be due to diabetes mellitus itself, and the same cannot be taken as significant.
5. The normal serum fibrinogen levels of the Indian population are not studied.

CONCLUSION

Anthropometric parameters of obesity were significantly higher in diabetic hypertensives than controls. Most of the Diabetic hypertensive patients have a central obesity pattern. The dyslipidemia pattern seen in diabetic hypertensives is elevated triglycerides, VLDL-C, LDL-C, Total cholesterol and TC/HDL and decreased HDL-C. Diabetic hypertensives have higher serum fibrinogen levels, and it is significantly related to BMI and lipid profile parameters.

REFERENCES

1. Park K. Diabetes mellitus – Epidemiology of chronic non-communicable diseases and condition, India. Chapter 6. In: Park's Textbook of preventive and social Medicine. 17th edition. Banarsidas Bhanot, Reprint 2002; pp. 294.
2. Munichoodappa C. Epidemiology and burden of type 2 diabetes mellitus, Bangalore. Type 2 Diabetes – the Indian scenario, Jayaram BM (ed). Microlabs Ltd, 2002; p. 13.
3. Friedwald WT, Levy RS, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
4. Physical status: The use and interpretation of anthropometry, Geneva: Report of a WHO Expert Committee. WHO Technical Report Series 1995; 854:324.
5. Lowe GDO, "Genetic variation at fibrinogen gene loci and plasma fibrinogen levels," J. Med. Genet 1992; 29: 480-482.
6. Bruno G, Paolo Cavallo-Perin, Ginseppe Bergero, Mileria Borra, Nicola D'Errico, Gian Franco Pagano, "Association of fibrinogen with glycemic control and albumin excretion rate in patients with NIDDM," Ann Intern Med 1996; 125: 653-657.
7. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M, "Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes," Metabolism, June 2002; 51(No. 6): 743-749.
8. Lam TH, Liu U, Janust ED, Lam KSL and Hedley AJ, "Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: A community with high prevalence of type-2 diabetes mellitus and impaired glucose tolerance", Diabetic Medicine 2000; 17: 798-806.
9. Om P Ganda, Charles F Arkin, "Hyperfibrinogenemia: An important risk factor for vascular complications in diabetes," Diabetes Care 1992; 15(No. 10): 1245-50.
10. Bruno G, Cavallo-Perin P, Barger G, Borra M, D'Errico N, Macchia G, Pagano G, "Hyperfibrinogenemia and metabolic syndrome in type-2 diabetes: a population based study", diabetes! Metabolism Research Reviews 2001; 17(2): 124-130.
11. Christophe Tribouilloy, Marcel Pltler, Laurent Colas, Michele Senni et al., "Fibrinogen is an independent marker for thoracic aortic atherosclerosis," Am. J. Cardiol 1998; 81: 321-326.
12. Eric Raynand, Antonia Perez-Martin, Jean Frederic Brun, Aomar Aissa- Benhaddad, Christine Fedou and Jacques Mercier, "Relationship between fibrinogen and insulin resistance," Atherosclerosis 2000; 150:365-370.
13. Ibeh N, Aneke J, Chide OE, Enemu E, Chukwuemeka U, Ibeh C. Plasma fibrinogen correlates with lipid profile in Nigerian patients with hypertension and diabetes coexisting with hypertension. Afr J Med Health Sci. 2016;15:1-6.
14. Han TS et al. Associations of body composition with type 2 diabetes mellitus. Diabetic Medicine, 1998; 15:129-135.
15. Sosenko JM et al. Plasma lipid levels at diagnosis in type 2 diabetic patients. Diabetic Medicine, 1993; 10:814-19.

16. Gary TC Ko, Juliana CN Chan, Lynn LW, Tsang and Clive S, Cockram, "Hyperfibrinogenemia did not improve after treating hyperglycemia in Chinese type-2 diabetic patients", *Ann. Clin. Biochem*, 2000; 37: 655-61.
17. Balleisen L, Bailey J, Epping PH, Schulte H and Van de Loo J, "Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: 1. Baseline data on the relation of age, gender, body weight, smoking, alcohol, pillusing and menopause", *Thromb. Haemost.* 1985; 54(2): 475-479.
18. Mariska Tuut and Hans-Werner Hense, "Smoking, other risk factors and fibrinogen levels," *Annals of Epid* May 2001; 11(4):232-238.
19. William B Kannel, Raipha BD, Agostino, Peter WF, Wilson, Albert J, Belanger MS et al., "Diabetes, fibrinogen and cardiovascular disease: The Framingham Experience," *Am. Heart J.* 1990; 120: 672-676.
20. Folsom AR, "Epidemiology of fibrinogen," *Eur Heart J.* March 1995; 16 Suppl A:21-3, Discussion 23-24.
21. Stefania Lamon-Fava, Peter W.F, Peter W.F. Wilson, and Ernst J. Schaefer. 1996;16:1509-1515.
22. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and coronary heart disease in women. *N Engl J Med.* 1990; 322:882-889.
23. Curb JD, Marcus EB. Body fat, coronary heart disease, and stroke in Japanese men. *Am J Clin Nutr.* 1991; 53:1615S.
24. Van Itallie TB. Obesity: adverse effects on health and longevity. *Am J Clin Nutr.* 1979; 32:2723-2733.
25. Barbara Glowinska, Mirosława Urban, Aliga Koput, Marzena Galar. New atherosclerosis risk factor in obese hypertensive and diabetic children and adolescents. *Atherosclerosis* 2003; 167(2):275-86.
26. Anjula Jain, Gupta HL, Shashi Narayan. Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. *JAPI* 2001; 49:227-30.
27. Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type-1 (insulin-dependent) diabetic patients with increased urinary albumin. *Diabetologia* 1988; 31: 142-45
28. Margita Eriksson: Relationship Between Plasma Fibrinogen and Coronary Heart Disease in Women: *Arterioscler Thromb Vasc Biol.* 1999;19:67-72.
29. Chowdhury Subhankar, Satinath Mukhopadhyay, Sengupta BR. Correlation between adiposity indices and plasma lipids in NIDDM. *Journal of Diabetic Association of India*; 30(2):28-31.
30. Hideki Asakawa, Katsuto Tokunaga, Fusao Kawakami. Relationship of abdominal fat with metabolic disorders in diabetes mellitus patients. *Diabetes Research and Clinical Practice* 2002; 55:139-49.
31. Om P Ganda, Charles F Arkin, "Hyperfibrinogenemia: An important risk factor for vascular complications in diabetes," *Diabetes Care* 1992; 15(No. 10): 1245-50.
32. Resch KL, Ernst E, "Determinants of fibrinogen," *Biorheology* 1995; 32(2-3): 154.
33. Ditschuneit HH, Flechtner-Mors-M, Adler G, "Fibrinogen in obesity before and after weight reduction," *Obes Res*, Jan 1995; 3(1):43-48.